These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

576 related items for PubMed ID: 26823566

  • 1. 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.
    Burger IA, Casanova R, Steiger S, Husmann L, Stolzmann P, Huellner MW, Curioni A, Hillinger S, Schmidtlein CR, Soltermann A.
    J Nucl Med; 2016 Jun; 57(6):849-54. PubMed ID: 26823566
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Combination of circulating tumor cells and 18F-FDG PET/CT for precision diagnosis in patients with non-small cell lung cancer.
    Sun M, Lu D, Li X, Wang J, Zhang L, Yang P, Yang Y, Shen J.
    Cancer Med; 2024 Sep; 13(18):e70216. PubMed ID: 39302034
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y, Onishi H, Nambu A, Araki T.
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
    Castello A, Toschi L, Rossi S, Finocchiaro G, Grizzi F, Mazziotti E, Qehajaj D, Rahal D, Lopci E.
    Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Analysis of Prognostic Values of Various PET Metrics in Preoperative 18F-FDG PET for Early-Stage Bronchial Carcinoma for Progression-Free and Overall Survival: Significantly Increased Glycolysis Is a Predictive Factor.
    Steiger S, Arvanitakis M, Sick B, Weder W, Hillinger S, Burger IA.
    J Nucl Med; 2017 Dec; 58(12):1925-1930. PubMed ID: 28490471
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Total lesion glycolysis by 18F-FDG PET/CT is independent prognostic factor in patients with advanced non-small cell lung cancer.
    Yıldırım F, Yurdakul AS, Özkaya S, Akdemir ÜÖ, Öztürk C.
    Clin Respir J; 2017 Sep; 11(5):602-611. PubMed ID: 26434685
    [Abstract] [Full Text] [Related]

  • 15. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
    Hu WD, Wang HC, Wang YB, Cui LL, Chen XH.
    Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
    Pellegrino S, Fonti R, Mazziotti E, Piccin L, Mozzillo E, Damiano V, Matano E, De Placido S, Del Vecchio S.
    Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy.
    Yan H, Wang R, Zhao F, Zhu K, Jiang S, Zhao W, Feng R.
    Acta Radiol; 2011 Jul 01; 52(6):646-50. PubMed ID: 21508201
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.